Literature DB >> 18729626

Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease.

Susanna Pietropaolo1, Joram Feldon, Benjamin K Yee.   

Abstract

The triple-transgenic mouse line (3 x Tg-AD) harboring PS1M146V, APPSwe, and taup301L transgenes represents the only transgenic model for Alzheimer's disease (AD) to date capturing both beta-amyloid and tau neuropathology. The present study provides an extensive behavioral characterization of the 3 x Tg-AD mouse line, evaluating the emergence of noncognitive and cognitive AD-like symptoms at two ages corresponding to the early (6-7 months) and advanced (12-13 months) stages of AD-pathology. Enhanced responsiveness to aversive stimulation was detected in mutant mice at both ages: the 3 x Tg-AD genotype enhanced acoustic startle response and facilitated performance in the cued-version of the water maze. These noncognitive phenotypes were accompanied by hyperactivity and reduced locomotor habituation in the open field at the older age. Signs of cognitive aberrations were also detected at both ages, but they were limited to associative learning. The present study suggests that this popular transgenic mouse model of AD has clear phenotypes beyond the cognitive domain, and their potential relationship to the cognitive phenotypes should be further explored.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729626     DOI: 10.1037/a0012520

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  24 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

Review 2.  Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia.

Authors:  A Shepherd; S Tyebji; A J Hannan; E L Burrows
Journal:  J Mol Neurosci       Date:  2016-09-16       Impact factor: 3.444

Review 3.  Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  Alzheimers Dement       Date:  2009-07       Impact factor: 21.566

4.  A longitudinal multimodal in vivo molecular imaging study of the 3xTg-AD mouse model shows progressive early hippocampal and taurine loss.

Authors:  Samuel Chiquita; Mário Ribeiro; João Castelhano; Francisco Oliveira; José Sereno; Marta Batista; Antero Abrunhosa; Ana C Rodrigues-Neves; Rafael Carecho; Filipa Baptista; Catarina Gomes; Paula I Moreira; António F Ambrósio; Miguel Castelo-Branco
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

5.  Gut Inflammation Induced by Dextran Sulfate Sodium Exacerbates Amyloid-β Plaque Deposition in the AppNL-G-F Mouse Model of Alzheimer's Disease.

Authors:  Mona Sohrabi; Heidi L Pecoraro; Colin K Combs
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

6.  3xTg-AD mice exhibit an activated central stress axis during early-stage pathology.

Authors:  Elaine K Hebda-Bauer; Tracy A Simmons; Andrew Sugg; Eren Ural; James A Stewart; James L Beals; Qiang Wei; Stanley J Watson; Huda Akil
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Hearing loss is an early biomarker in APP/PS1 Alzheimer's disease mice.

Authors:  Yang Liu; Shu Fang; Li-Man Liu; Yan Zhu; Chang-Ri Li; Kaitian Chen; Hong-Bo Zhao
Journal:  Neurosci Lett       Date:  2019-12-20       Impact factor: 3.046

Review 8.  Rodent models for Alzheimer's disease drug discovery.

Authors:  Daniela Puzzo; Walter Gulisano; Agostino Palmeri; Ottavio Arancio
Journal:  Expert Opin Drug Discov       Date:  2015-04-30       Impact factor: 6.098

Review 9.  APP transgenic mice: their use and limitations.

Authors:  Claudia Balducci; Gianluigi Forloni
Journal:  Neuromolecular Med       Date:  2010-12-09       Impact factor: 3.843

10.  Modeling Alzheimer's disease: from past to future.

Authors:  Claudia Saraceno; Stefano Musardo; Elena Marcello; Silvia Pelucchi; Monica Di Luca
Journal:  Front Pharmacol       Date:  2013-06-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.